Permeability of Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and Lipophilicity
Overview
Affiliations
Purpose: To determine the effects of solute molecular weight and lipophilicity on the permeability of a retinal pigment epithelium (RPE)-choroid preparation.
Methods: Fresh RPE-choroid specimens from bovine eyes were placed in diffusion chambers for permeability experiments with carboxyfluorescein, fluorescein isothiocyanate (FITC)-labeled dextrans with molecular masses from 4 to 80 kDa, and beta-blockers exhibiting a wide range of lipophilicity (atenolol, nadolol, pindolol, timolol, metoprolol, and betaxolol). Permeability experiments were performed both in the choroid-to-retina (inward) direction and in the retina-to-choroid (outward) direction. Carboxyfluorescein and FITC-dextrans were determined by fluorometry, and beta-blockers by HPLC. The transepithelial electrical resistance and potential difference were monitored during the experiments.
Results: Permeability of the fluorescent FITC-dextran probes through RPE-choroid decreased significantly with the increasing size of the probe. RPE-choroid was 35 times more permeable to carboxyfluorescein (376 Da) than to FITC-dextran 80 kDa. The permeabilities of lipophilic beta-blockers were up to 8 and 20 times higher than that of hydrophilic atenolol and carboxyfluorescein, respectively. The lag time of solute flux across the RPE-choroid increased with the molecular weight and lipophilicity. Compared with published data on isolated sclera, bovine RPE-choroid was 10 to 100 times less permeable to hydrophilic compounds and macromolecules. The permeability of lipophilic molecules in RPE-choroid was in the same range as in the sclera.
Conclusions: RPE is a major barrier and may be the rate-limiting factor in the retinal delivery of hydrophilic drugs and macromolecules through the transscleral route. For lipophilic molecules, RPE-choroid, and sclera are approximately equal barriers.
Jin B, Lu K, Gao W, Liu Y, Wang M, Zhang X Int J Nanomedicine. 2024; 19:7799-7816.
PMID: 39099794 PMC: 11297587. DOI: 10.2147/IJN.S467949.
Guidi L, Cascone M, Rosellini E Heliyon. 2024; 10(5):e26616.
PMID: 38434257 PMC: 10906429. DOI: 10.1016/j.heliyon.2024.e26616.
Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.
Zhou Y, Xu M, Shen W, Xu Y, Shao A, Xu P Adv Healthc Mater. 2024; 13(17):e2304626.
PMID: 38406994 PMC: 11468720. DOI: 10.1002/adhm.202304626.
Progress in Ocular Drug Delivery: Challenges and Constraints.
Rupenthal I, Agarwal P Handb Exp Pharmacol. 2023; 284:267-288.
PMID: 37620616 DOI: 10.1007/164_2023_693.
Peng X, Zhang T, Liu R, Jin X Mol Cell Biochem. 2023; 479(6):1319-1333.
PMID: 37402019 DOI: 10.1007/s11010-023-04798-w.